← Leaderboards
Huiping Liu
University Of Chicago
$6,323,956
Attributed
$9,105,203
Total exposure
8
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2012–25$2M$1.5M$1M$500K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,105,203 · 8
By mechanism
R01$6,109,822 · 4
UH3$1,178,472 · 1
R00$883,186 · 1
UG3$800,000 · 1
K99$133,723 · 1
Most similar at University Of Chicago
Same institution · by research overlap
- Jing Chen$12,817,541
- Deniz Nesli Dolcen$377,272
- Benjamin Nicholson$100,012
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsTechnologyBreastMolecularMalignant NeoplasmsIn VivoUniversitiesPreventPreclinical StudyAntibodiesNeoplasm MetastasisNovel TherapeuticsTumorMalignant Breast NeoplasmSpecimenDetectionProteinsBaseUnited StatesMammary NeoplasmsPropertyIn VitroGenesBreast Cancer Metastasis
Grant awards (25)
Clinical analysis and therapeutic development of exosomal ACE2$697,517
R01 · FY2025 · AI · contact PI
Develop a novel therapy with immuno- and onco-targeting dual efficacies to treat the triple negative breast cancer$661,072
R01 · FY2025 · CA
Novel functions of PlexinB2 in circulating tumor cell clusters$545,983
R01 · FY2025 · CA · contact PI
Clinical analysis and therapeutic development of exosomal ACE2$697,517
R01 · FY2024 · AI · contact PI
Molecular mechanisms underlying circulating tumor cell aggregation$347,701
R01 · FY2024 · CA · contact PI
Clinical analysis and therapeutic development of exosomal ACE2$748,517
R01 · FY2023 · AI · contact PI
A streamlined platform for phosphoproteome mapping of human tissues$578,472
UH3 · FY2023 · CA
Molecular mechanisms underlying circulating tumor cell aggregation$358,680
R01 · FY2023 · CA · contact PI
Clinical analysis and therapeutic development of exosomal ACE2$779,400
R01 · FY2022 · AI · contact PI
A streamlined platform for phosphoproteome mapping of human tissues$600,000
UH3 · FY2022 · CA
Molecular mechanisms underlying circulating tumor cell aggregation$358,680
R01 · FY2022 · CA · contact PI
Molecular mechanisms underlying circulating tumor cell aggregation$22,016
R01 · FY2022 · CA · contact PI
Molecular mechanisms underlying circulating tumor cell aggregation$478,017
R01 · FY2021 · CA · contact PI
A streamlined platform for phosphoproteome mapping of human tissues$400,000
UG3 · FY2021 · CA
A streamlined platform for phosphoproteome mapping of human tissues$400,000
UG3 · FY2020 · CA
Molecular mechanisms underlying circulating tumor cell aggregation$361,425
R01 · FY2020 · CA · contact PI
Molecular mechanisms underlying circulating tumor cell aggregation$53,297
R01 · FY2020 · CA · contact PI
Identifying a network of microRNAs and genes that regulate breast tumor metastasis$32,964
R00 · FY2017 · CA · contact PI
Identifying a network of microRNAs and genes that regulate breast tumor metastasis$197,286
R00 · FY2016 · CA · contact PI
Identifying a network of microRNAs and genes that regulate breast tumor metastasis$65,899
R00 · FY2016 · CA · contact PI
Identifying a network of microRNAs and genes that regulate breast tumor metastasi$41,869
R00 · FY2016 · CA · contact PI
Identifying a network of microRNAs and genes that regulate breast tumor metastasi$246,615
R00 · FY2015 · CA · contact PI
Identifying a network of miRNAs and genes that regulate breast tumor metastasis$57,024
R00 · FY2015 · CA · contact PI
Identifying a network of microRNAs and genes that regulate breast tumor metastasi$241,529
R00 · FY2014 · CA · contact PI
Identifying a network of microRNAs and genes that regulate breast tumor metastasi$133,723
K99 · FY2012 · CA · contact PI